David J Jackson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3496563/publications.pdf

Version: 2024-02-01

67 papers	3,782 citations	185998 28 h-index	138251 58 g-index
67 all docs	67 docs citations	67 times ranked	4016 citing authors

#	Article	IF	Citations
1	Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respiratory Medicine,the, 2022, 10, 47-58.	5.2	74
2	Prescribing Patterns and Treatment Adherence in Patients with Asthma During the COVID-19 Pandemic. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 100-107.e2.	2.0	17
3	Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma: a pilot randomised controlled trial. Thorax, 2022, 77, 950-959.	2.7	7
4	Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 422-432.	2.0	28
5	Rhinovirus Infections and Their Roles in Asthma: Etiology and Exacerbations. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 673-681.	2.0	46
6	Safety of eosinophil depletion. , 2022, , 238-252.		2
7	Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1202-1216.e23.	2.0	22
8	The prevalence of mucus plugging in severe eosinophilic asthma and its relationship to clinical efficacy of antiâ€“IL-5R treatment. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1102-1103.e1.	2.0	8
9	Eosinophils and eosinophilic immune dysfunction in health and disease. European Respiratory Review, 2022, 31, 210150.	3.0	32
10	Eosinophilic asthma. , 2022, , 73-99.		2
11	Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1534-1544.e4.	2.0	21
12	Disease-modifying anti-asthmatic drugs. Lancet, The, 2022, 399, 1664-1668.	6.3	42
13	Improving Care in Eosinophil-Associated Diseases: A Charter. Advances in Therapy, 2022, 39, 2323-2341.	1.3	6
14	COVIDâ€19 in the absence of eosinophils: The outcome of confirmed SARSâ€CoVâ€2 infection whilst on treatment with benralizumab. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2558-2560.	2.7	5
15	Assessing adherence to inhaled therapies in asthma and the emergence of electronic monitoring devices. European Respiratory Review, 2022, 31, 210271.	3.0	8
16	Benralizumab after subâ€optimal response to mepolizumab in severe eosinophilic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1890-1893.	2.7	33
17	Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. Thorax, 2021, 76, 220-227.	2.7	83
18	Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest, 2021, 159, 496-506.	0.4	159

#	Article	IF	Citations
19	Composite type-2 biomarker strategy versus a symptomâ€“risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 57-68.	5.2	88
20	Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2238-2241.	2.7	15
21	Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy. European Respiratory Journal, 2021, 57, 2100166.	3.1	1
22	Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 344-356.	1.4	13
23	Potential Severe Asthma Hidden in UK Primary Care. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1612-1623.e9.	2.0	42
24	Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies. Annual Review of Immunology, 2021, 39, 719-757.	9.5	69
25	The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2093-2096.e1.	2.0	37
26	Real-World Effectiveness of Antiâ€“IL-5/5R Therapy in Severe Atopic Eosinophilic Asthma with Fungal Sensitization. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2315-2320.e1.	2.0	21
27	Prevention and Treatment of Asthma Exacerbations in Adults. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2578-2586.	2.0	13
28	Biologics in severe asthma: Which one, When and Where?. Clinical and Experimental Allergy, 2021, 51, 1225-1228.	1.4	5
29	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3997-4004.	2.0	74
30	Workup of Severe Asthma. Chest, 2021, 160, 2019-2029.	0.4	18
31	Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2021, 148, 283-291.	1.5	14
32	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. Journal of Pragmatic and Observational Research, 2021, Volume 12, 93-104.	1.1	32
33	Recommendations following a modified UK-Delphi consensus study on best practice for referral and management of severe asthma. BMJ Open Respiratory Research, 2021, 8, e001057.	1.2	4
34	Eosinophilic and Noneosinophilic Asthma. Chest, 2021, 160, 814-830.	0.4	109
35	Pulmonary Innate Lymphoid Cell Responses during Rhinovirus-induced Asthma ExacerbationsInÂVivo: A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1259-1273.	2.5	22
36	Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clinic Proceedings, 2021, 96, 2694-2707.	1.4	103

#	Article	IF	Citations
37	The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?. ERJ Open Research, 2021, 7, 00768-2020.	1.1	14
38	Introducing the Severe Asthma Series of Invited Reviews. Chest, 2021, 160, 1151-1152.	0.4	1
39	Characteristics of patients in platform C19, a COVID-19 research database combining primary care electronic health record and patient reported information. PLoS ONE, 2021, 16, e0258689.	1.1	2
40	A pragmatic guide to choosing biologic therapies in severe asthma. Breathe, 2021, 17, 210144.	0.6	20
41	Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Advances in Therapy, 2020, 37, 718-729.	1.3	48
42	Characterization of Severe Asthma Worldwide. Chest, 2020, 157, 790-804.	0.4	165
43	Biologic treatment options for severe asthma. Current Opinion in Immunology, 2020, 66, 151-160.	2.4	23
44	Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis. ERJ Open Research, 2020, 6, 00451-2020.	1.1	33
45	Inflammatory and microbiological associations with near-fatal asthma requiring extracorporeal membrane oxygenation. ERJ Open Research, 2020, 6, 00267-2019.	1.1	11
46	Response. Chest, 2020, 158, 2230-2231.	0.4	0
47	Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. ERJ Open Research, 2020, 6, 00311-2019.	1.1	26
48	Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma. European Respiratory Journal, 2020, 55, 1902259.	3.1	55
49	Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab. Drug Safety, 2020, 43, 409-425.	1.4	47
50	Real-World Effectiveness and the Characteristics of a â€œSuper-Responderâ€•to Mepolizumab in Severe Eosinophilic Asthma. Chest, 2020, 158, 491-500.	0.4	135
51	M1-like macrophages are potent producers of anti-viral interferons and M1-associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma exacerbations. EBioMedicine, 2020, 54, 102734.	2.7	37
52	Prevalence and recovery of adrenal insufficiency in steroid-dependent asthma patients receiving biologic therapy. European Respiratory Journal, 2020, 56, 1902273.	3.1	10
53	Late Breaking Abstract - Defining a severe asthma super-responder: findings from a Delphi process. , 2020, , .		5
54	Diagnosing adrenal insufficiency using ACTH stimulation test. European Respiratory Journal, 2020, 56, 2002149.	3.1	2

#	Article	IF	Citations
55	Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nature Medicine, 2017, 23, 681-691.	15.2	260
56	A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN-Î³ and IFN-Î») and Type 2 Inflammation (IL-5 and IL-13). EBioMedicine, 2017, 19, 128-138.	2.7	102
57	Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illness. Journal of Allergy and Clinical Immunology, 2017, 140, 909-920.	1.5	178
58	Rhinovirus induction of fractalkine (CX3CL1) in airway and peripheral blood mononuclear cells in asthma. PLoS ONE, 2017, 12, e0183864.	1.1	7
59	Are emerging PGD2 antagonists a promising therapy class for treating asthma?. Expert Opinion on Emerging Drugs, 2016, 21, 359-364.	1.0	20
60	Rhinovirus-induced VP1-specific Antibodies are Group-specific and Associated With Severity of Respiratory Symptoms. EBioMedicine, 2015, 2, 64-70.	2.7	24
61	Interleukin-18 Is Associated With Protection Against Rhinovirus-Induced Colds and Asthma Exacerbations. Clinical Infectious Diseases, 2015, 60, 1528-1531.	2.9	19
62	The influence of asthma control on the severity of virus-induced asthma exacerbations. Journal of Allergy and Clinical Immunology, 2015, 136, 497-500.e3.	1.5	42
63	Pathogenesis of Viral Infection in Exacerbations of Airway Disease. Annals of the American Thoracic Society, 2015, 12, S115-S132.	1.5	76
64	Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Science Translational Medicine, 2014, 6, 256ra134.	5.8	280
65	IL-33â€“Dependent Type 2 Inflammation during Rhinovirus-induced Asthma Exacerbations In Vivo. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1373-1382.	2.5	500
66	Role of interleukin 33 in respiratory allergy and asthma. Lancet Respiratory Medicine,the, 2014, 2, 226-237.	5.2	60
67	The role of viruses in acute exacerbations of asthma. Journal of Allergy and Clinical Immunology, 2010, 125, 1178-1187.	1.5	305